株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

IMMUNOMEDICS, INC - 製品パイプライン分析

Immunomedics Inc - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 224583
出版日 ページ情報 英文 89 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
IMMUNOMEDICS, INC - 製品パイプライン分析 Immunomedics Inc - Product Pipeline Review - 2016
出版日: 2016年12月30日 ページ情報: 英文 89 Pages
概要

Immunomedics, Inc.はバイオ製薬会社で、癌や自己免疫疾患などの深刻な病気治療のためのモノクローナル抗体による製品を開発しています。そして新たな生物医薬品を開発することで業績を拡大しています。

当レポートでは、Immunomedics, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Immunomedics, Inc.の基本情報

Immunomedics, Inc.の概要

  • 主要情報
  • 企業情報

Immunomedics, Inc.:R&Dの概要

  • 主な治療範囲

Immunomedics, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Immunomedics, Inc.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Immunomedics, Inc.:薬剤プロファイル

  • epratuzumab
  • yttrium Y 90 clivatuzumab tetraxetan
  • IMMU-130
  • IMMU-132
  • veltuzumab
  • IMMU-110
  • milatuzumab
  • TF-2
  • IMMU-114
  • 1R-(15)-(15)
  • 1R-(E1)-(E1)
  • Interferon Lambda-1 Linked Fab Dimer
  • TF-12
  • hA19 Antibody

Immunomedics, Inc.:パイプライン分析

  • 薬効分類別
  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Immunomedics, Inc.:最近のパイプライン動向

Immunomedics, Inc.:休止中のプロジェクト

Immunomedics, Inc.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • veltuzumab
  • ■Immunomedics, Inc.:企業発表

Immunomedics, Inc.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08188CDB

Summary

Global Markets Direct's, 'Immunomedics Inc - Product Pipeline Review - 2016', provides an overview of the Immunomedics Inc's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immunomedics Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Immunomedics Inc
  • The report provides overview of Immunomedics Inc including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Immunomedics Inc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Immunomedics Inc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Immunomedics Inc's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Immunomedics Inc
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Immunomedics Inc's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Immunomedics Inc Snapshot
    • Immunomedics Inc Overview
    • Key Facts
  • Immunomedics Inc - Research and Development Overview
    • Key Therapeutic Areas
  • Immunomedics Inc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Immunomedics Inc - Pipeline Products Glance
    • Immunomedics Inc - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Immunomedics Inc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Immunomedics Inc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Immunomedics Inc - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Immunomedics Inc - Drug Profiles
    • 14-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 15-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 19-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 1R-15-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 1R-2b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 1R-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 1R-E1-E1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 20-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 202-b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C2-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E1-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epratuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Hex-hR1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMMU-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMMU-114 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMMU-140 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • labetuzumab govitecan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M1-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • milatuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target CD19 for B-Cell Hematologic Malignancies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target CEACAM6 for Colon Cancer and Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monocloncal Antibody to Target CD-19 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize Interferon Lamda Receptor 1 for Oncology and Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sacituzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TF-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TF-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • veltuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yttrium Y 90 epratuzumab tetraxetan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Immunomedics Inc - Pipeline Analysis
    • Immunomedics Inc - Pipeline Products by Target
    • Immunomedics Inc - Pipeline Products by Route of Administration
    • Immunomedics Inc - Pipeline Products by Molecule Type
    • Immunomedics Inc - Pipeline Products by Mechanism of Action
  • Immunomedics Inc - Dormant Projects
  • Immunomedics Inc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • clivatuzumab tetraxetan
      • epratuzumab
      • ImmuRAIT-LL2
      • veltuzumab
  • Immunomedics Inc - Company Statement
  • Immunomedics Inc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Immunomedics Inc, Key Facts
  • Immunomedics Inc - Pipeline by Indication, 2016
  • Immunomedics Inc - Pipeline by Stage of Development, 2016
  • Immunomedics Inc - Monotherapy Products in Pipeline, 2016
  • Immunomedics Inc - Partnered Products in Pipeline, 2016
  • Immunomedics Inc - Partnered Products/ Combination Treatment Modalities, 2016
  • Immunomedics Inc - Phase III, 2016
  • Immunomedics Inc - Phase II, 2016
  • Immunomedics Inc - Phase I, 2016
  • Immunomedics Inc - Preclinical, 2016
  • Immunomedics Inc - Discovery, 2016
  • Immunomedics Inc - Unknown, 2016
  • Immunomedics Inc - Pipeline by Target, 2016
  • Immunomedics Inc - Pipeline by Route of Administration, 2016
  • Immunomedics Inc - Pipeline by Molecule Type, 2016
  • Immunomedics Inc - Pipeline Products by Mechanism of Action, 2016
  • Immunomedics Inc - Dormant Developmental Projects,2016
  • Immunomedics Inc - Discontinued Pipeline Products, 2016
  • Immunomedics Inc, Other Locations
  • Immunomedics Inc, Subsidiaries

List of Figures

  • Immunomedics Inc - Pipeline by Top 10 Indication, 2016
  • Immunomedics Inc - Pipeline by Stage of Development, 2016
  • Immunomedics Inc - Monotherapy Products in Pipeline, 2016
  • Immunomedics Inc - Pipeline by Top 10 Target, 2016
  • Immunomedics Inc - Pipeline by Route of Administration, 2016
  • Immunomedics Inc - Pipeline by Molecule Type, 2016
  • Immunomedics Inc - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top